_version_ 1784859563402461184
author Reyes-Vallejo, Tania
Conde-Rodríguez, Ileana
Serna-Villalobos, Jocelyn
Ramírez-Díaz, Ivonne
Pérez-Villalobos, Gabriela
Delgado-López, Guadalupe
Vázquez-Zamora, Víctor Javier
Gutierrez-Quiroz, Claudia Teresita
Ávila-Jiménez, Laura
García-Carrancá, Alejandro
Martínez-Acosta, Liliana
Santos-López, Gerardo
Reyes-Leyva, Julio
Vallejo-Ruiz, Verónica
author_facet Reyes-Vallejo, Tania
Conde-Rodríguez, Ileana
Serna-Villalobos, Jocelyn
Ramírez-Díaz, Ivonne
Pérez-Villalobos, Gabriela
Delgado-López, Guadalupe
Vázquez-Zamora, Víctor Javier
Gutierrez-Quiroz, Claudia Teresita
Ávila-Jiménez, Laura
García-Carrancá, Alejandro
Martínez-Acosta, Liliana
Santos-López, Gerardo
Reyes-Leyva, Julio
Vallejo-Ruiz, Verónica
author_sort Reyes-Vallejo, Tania
collection PubMed
description
format Online
Article
Text
id pubmed-9792111
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-97921112022-12-27 Response to Article “Serum Levels of Galectin-9 are Increased in Cervical Cancer Patients and are Higher in Advanced Clinical Stages” [Response to Letter] Reyes-Vallejo, Tania Conde-Rodríguez, Ileana Serna-Villalobos, Jocelyn Ramírez-Díaz, Ivonne Pérez-Villalobos, Gabriela Delgado-López, Guadalupe Vázquez-Zamora, Víctor Javier Gutierrez-Quiroz, Claudia Teresita Ávila-Jiménez, Laura García-Carrancá, Alejandro Martínez-Acosta, Liliana Santos-López, Gerardo Reyes-Leyva, Julio Vallejo-Ruiz, Verónica Onco Targets Ther Response to Letter Dove 2022-12-22 /pmc/articles/PMC9792111/ /pubmed/36579183 http://dx.doi.org/10.2147/OTT.S399119 Text en © 2022 Reyes-Vallejo et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Response to Letter
Reyes-Vallejo, Tania
Conde-Rodríguez, Ileana
Serna-Villalobos, Jocelyn
Ramírez-Díaz, Ivonne
Pérez-Villalobos, Gabriela
Delgado-López, Guadalupe
Vázquez-Zamora, Víctor Javier
Gutierrez-Quiroz, Claudia Teresita
Ávila-Jiménez, Laura
García-Carrancá, Alejandro
Martínez-Acosta, Liliana
Santos-López, Gerardo
Reyes-Leyva, Julio
Vallejo-Ruiz, Verónica
Response to Article “Serum Levels of Galectin-9 are Increased in Cervical Cancer Patients and are Higher in Advanced Clinical Stages” [Response to Letter]
title Response to Article “Serum Levels of Galectin-9 are Increased in Cervical Cancer Patients and are Higher in Advanced Clinical Stages” [Response to Letter]
title_full Response to Article “Serum Levels of Galectin-9 are Increased in Cervical Cancer Patients and are Higher in Advanced Clinical Stages” [Response to Letter]
title_fullStr Response to Article “Serum Levels of Galectin-9 are Increased in Cervical Cancer Patients and are Higher in Advanced Clinical Stages” [Response to Letter]
title_full_unstemmed Response to Article “Serum Levels of Galectin-9 are Increased in Cervical Cancer Patients and are Higher in Advanced Clinical Stages” [Response to Letter]
title_short Response to Article “Serum Levels of Galectin-9 are Increased in Cervical Cancer Patients and are Higher in Advanced Clinical Stages” [Response to Letter]
title_sort response to article “serum levels of galectin-9 are increased in cervical cancer patients and are higher in advanced clinical stages” [response to letter]
topic Response to Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792111/
https://www.ncbi.nlm.nih.gov/pubmed/36579183
http://dx.doi.org/10.2147/OTT.S399119
work_keys_str_mv AT reyesvallejotania responsetoarticleserumlevelsofgalectin9areincreasedincervicalcancerpatientsandarehigherinadvancedclinicalstagesresponsetoletter
AT conderodriguezileana responsetoarticleserumlevelsofgalectin9areincreasedincervicalcancerpatientsandarehigherinadvancedclinicalstagesresponsetoletter
AT sernavillalobosjocelyn responsetoarticleserumlevelsofgalectin9areincreasedincervicalcancerpatientsandarehigherinadvancedclinicalstagesresponsetoletter
AT ramirezdiazivonne responsetoarticleserumlevelsofgalectin9areincreasedincervicalcancerpatientsandarehigherinadvancedclinicalstagesresponsetoletter
AT perezvillalobosgabriela responsetoarticleserumlevelsofgalectin9areincreasedincervicalcancerpatientsandarehigherinadvancedclinicalstagesresponsetoletter
AT delgadolopezguadalupe responsetoarticleserumlevelsofgalectin9areincreasedincervicalcancerpatientsandarehigherinadvancedclinicalstagesresponsetoletter
AT vazquezzamoravictorjavier responsetoarticleserumlevelsofgalectin9areincreasedincervicalcancerpatientsandarehigherinadvancedclinicalstagesresponsetoletter
AT gutierrezquirozclaudiateresita responsetoarticleserumlevelsofgalectin9areincreasedincervicalcancerpatientsandarehigherinadvancedclinicalstagesresponsetoletter
AT avilajimenezlaura responsetoarticleserumlevelsofgalectin9areincreasedincervicalcancerpatientsandarehigherinadvancedclinicalstagesresponsetoletter
AT garciacarrancaalejandro responsetoarticleserumlevelsofgalectin9areincreasedincervicalcancerpatientsandarehigherinadvancedclinicalstagesresponsetoletter
AT martinezacostaliliana responsetoarticleserumlevelsofgalectin9areincreasedincervicalcancerpatientsandarehigherinadvancedclinicalstagesresponsetoletter
AT santoslopezgerardo responsetoarticleserumlevelsofgalectin9areincreasedincervicalcancerpatientsandarehigherinadvancedclinicalstagesresponsetoletter
AT reyesleyvajulio responsetoarticleserumlevelsofgalectin9areincreasedincervicalcancerpatientsandarehigherinadvancedclinicalstagesresponsetoletter
AT vallejoruizveronica responsetoarticleserumlevelsofgalectin9areincreasedincervicalcancerpatientsandarehigherinadvancedclinicalstagesresponsetoletter